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In fields such as cancer biology and regenerative medicine, obtaining information regarding cell bio-distribution,
tropism, status, and other cellular functions are highly desired. Understanding cancer behaviors including metastasis
is important for developing effective cancer treatments, while assessing the fate of therapeutic cells following
implantation is critical to validate the efficacy and efficiency of the therapy. For visualization purposes with medical
imaging modalities (e.g. magnetic resonance imaging), cells can be labeled with contrast agents (e.g. iron-oxide
nanoparticles), which allows their identification from the surrounding environment. Despite the success of revealing cell
biodistribution in vivo, most of the existing agents do not provide information about the status and functions of cells
following transplantation. The emergence of aptamers, single-stranded RNA or DNA oligonucleotides of 15 to 60 bases
in length, is a promising solution to address this need. When aptamers bind specifically to their cognate molecules, they
undergo conformational changes which can be transduced into a change of imaging contrast (e.g. optical, magnetic
resonance). Thus by monitoring this signal change, researchers can obtain information about the expression of the
target molecules (e.g. mRNA, surface markers, cell metabolites), which offer clues regarding cell status/function in
a non-invasive manner. In this review, we summarize recent efforts to utilize aptamers as biosensors for monitoring
the status and function of transplanted cells. We focus on cancer cell tracking for cancer study, stem cell tracking
for regenerative medicine, and immune cell (e.g. dendritic cells) tracking for immune therapy.
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Over the past decade, the field of cell tracking, which
includes monitoring cellular location, function and be-
havior in real time through various imaging modalities,
has experienced rapid progression. The successful clinical
translation of therapeutics have motivated researchers to
seek a comprehensive understanding of the in vivo fate of
transplanted cells [1,2]. For instance, tracking cancer cells
in their native environment can yield data on their biodis-
tribution, tropism, status and functions (e.g. metastasis),
which can significantly impact the success of cancer ther-
apy [3-5]. Meanwhile, revealing the fate and functions of
therapeutic cells following their implantation can help
optimize the procedure of cellular therapy (e.g. dosage,
injection frequency, and administration protocol) [6].* Correspondence: cjxu@ntu.edu.sg
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unless otherwise stated.In both preclinical and clinical studies, cells can be mon-
itored and tracked through imaging modalities such as:
optical imaging, positron emission tomography (PET)/
single photon emission computed tomography (SPECT),
X-ray computed tomography (CT), and magnetic reson-
ance imaging (MRI). Typically, cells of interest are labeled
with contrast agents that provide detectable signals to dis-
tinguish them from bystander cells. For example in optical
imaging, fluorescent/bioluminescent molecules and nano-
particles are used as contrast agents [7,8]. On the other
hand, PET/SPECT employs radio-isotope labeling agents
such as 18F-FDG [9,10]. Agents with high X-ray absoption
properties (e.g. Omnipaque) meanwhile, are used to label
cells for X-ray imaging and CT [11]. Lastly, MRI utilizes
gadolinium or iron oxide nanoparticles to modify the
magnetic relaxation time of the selected tissue [12,13].
Although these contrast agents have greatly assisted
researchers to visualize the shape, morphology and
motion of cells, tissues, and organs, few have the ability
to specifically reveal the status and function of cells attd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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generally suffer from significant uptake and transfer to
non-target cells [14-16].
Ideally, contrast agents for cell tracking should effi-
ciently label cells of interest, persist within the cells for a
period of time with minimal transfer to bystanders, and
provide a detectable change in signal to reflect changes
in cell status and/or function.
Review
Aptamer-based biosensors
Aptamers are single-stranded RNA or DNA oligonucleo-
tides usually 15 to 60 bases in length that can bind spe-
cifically to target molecules. Typically, aptamers can be
generated from a selection process termed as SELEX (sys-
tematic evolution of ligands by exponential enrichment)
[17,18]. In SELEX, an initial library consisting of >1013 ran-
dom oligonucleotides is enriched by an iterative elimination
and PCR process to selectively amplify sequences posses-
sing high affinity to the pre-determined target.
With the versatility of target molecules for the SELEX
process, a wide range of aptamer applications have been
developed, such as immobilized sensing molecules (apta-
sensors), since its introduction in 1990 [17]. For instance,
aptamers have been conjugated on the surface of gold
nanoparticles (AuNP) to recognize and detect the pres-
ence of small analytes including K+, ATP, and cocaine
[19-21], as well as larger proteins like thrombin and
platelet-derived growth factors (PDGF) [22,23]. These
aptasensors rely on the highly specific, structure-switching
ability of aptamers; they undergo drastic secondary or
tertiary folding from their initial conformation upon
binding with their target molecules [24]. By labeling
aptamers with quencher and fluorophore dyes at their 5’
and 3’ ends, a target binding event, which causes a
displacement of the two dyes can be transduced to a
change in fluorescent signal as a result of Förster reson-
ance energy transfer (FRET) principles (Figure 1A) [25].
While the application of SELEX for whole-cells target
(cell-SELEX) is relatively new, it has progressed rapidly
over the past decade. In comparison to other targeting
ligands such as antibodies, aptamers exhibit several
advantages. Firstly, the synthesis of aptamer is an
entirely chemical process that can be scaled up with
consistency and used to incorporate a diverse range of
functional moieties [26-28]. In addition when compared
to antibodies, aptamer probes are low in immunogenicity
and considerably stable in a wide range of pH (4–9),
temperature, and organic solvents [29-31]. Furthermore,
the molecular-level resolution of aptamers can be utilized
to transduce signal changes related to cellular status.
By employing aptamers targeted at a specific cell sur-
face marker for example, the up/down-regulation of
that particular marker can be monitored, as a mean toevaluate cellular functionality [32-34]. As will be elabo-
rated later, this approach has been successfully utilized
to evaluate embryonic stem cell (ESC) differentiation
processes [35]. Meanwhile, the high specificity and low
dissociation constant (Kd) (in the range of nano to
pico-molar) of aptamers help to minimize the risk of
agent transfer to non-target cells [36]. Taken together,
these properties make aptamers an excellent tool to
accomplish ideal cell tracking (i.e. complete monitoring of
cellular biodistribution, status and functions), for both
diseased cells (e.g. cancer cells) and therapeutic cells
(immune cells & stem cells).
Lastly, it is also noteworthy that cell-SELEX (Figure 1B)
does not require prior knowledge regarding the surface
signature of the target cells. Instead, the selection of apta-
mers involves repetitive elimination of sequences that bind
to non-target cells [37-39]. For example to screen apta-
mers for targeting human T cell lymphoblast-like cell
line CCRF-CEM cells, a sequence library was continu-
ously enriched for sequences that bind to CCRF-CEM
cells but not Ramos cells. The library enrichment was
quantitatively evaluated over the different cycles of
incubation and selection steps by monitoring the fluores-
cence of CCRF-CEM cells through flow cytometry [40].
Aptamers for cell tracking
Early applications of aptamers for cell tracking were fo-
cused on diseased cells. Particularly, scientists have uti-
lized aptamers as “molecular-level beacons” to better
understand the behavior of cancer cells in vivo [40,41]. By
selecting aptamers that recognize cancer antigens and
coupling them with a contrast agent, such as quantum
dots (QDs), fluorescent dyes, or iron oxide nanoparticles
(IO-NPs) [28,42,43], cancer cells can be non-invasively
monitored for their location, growth progression, meta-
static migration, etc. [33,44,45]. As compared to end-point
analysis (e.g. histology of sample biopsies) which is a
destructive process [46,47], aptamers provide real-time
tracking, which more accurately represents the dynamic
in vivo microenvironment, while minimizing the number
of preclinical experimental subjects [48,49]. Given the re-
cent advancements in regenerative medicine, aptamers are
beginning to be incorporated in the development of cellu-
lar therapy and tissue engineering. In such applications,
aptamers are potentially beneficial not only to reveal the
biodistribution and tropism of cells, but also to report
their successful utilization in vivo (i.e. achieving desirable
therapeutic effects and functional tissues) [50].
Below, we first describe the applications of aptamers
for tracking cancer cells. Subsequently, aptamer applica-
tions for two important cell types in the field of regen-
erative medicine (stem cells and immune cells) will be
discussed in detail. An overview of the aptamer-based
cell tracking applications can be found in Figure 2.
Figure 1 Mechanism and selection process of aptamer probes. A) Hybridization of aptamer probes with their target molecule involves a
structural change (from i to ii), which triggers fluorescent signal restoration due to the increased distance between the fluorophore and the
quencher. B) Selection steps within one cycle of cell-SELEX. Briefly, a library of single-stranded sequences is incubated with target cells. Following
the washing procedures, negative selection is done to remove sequences that bind non-specifically. Subsequently, the resulting sequences are
PCR-amplified before proceeding to the next cycle. Part B is adapted with permission from ref. [38]. Sefah K, Shangguan D, Xiong X, O’Donoghue
MB, Tan W: Development of DNA aptamers using Cell-SELEX. Nature protocols 2010, 5:1169–1185. Copyright 2010 by Nature Publishing Group.
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Efforts using aptamer-based cancer cell tracking can be
grouped under the different imaging modalities, includ-
ing optical, PET/SPECT, X-ray/CT, and MRI.
Optical imaging is perhaps the most common means
of aptamer tracking. Its distinctive properties such as
easy accessibility, low instrumentation cost, high reso-
lution (allowing visualization of single cells) and good
spatiotemporal sensitivity, promote utilization in many
tracking applications. Furthermore, the recent advance-
ments of multi-photon and intra-vital microscopy and
optical probes in the near-infrared region (NIR) (700-
900 nm) have permitted in vivo optical imaging on small
animals or for near-surface observation [51-53].
By tagging fluorophore directly/non-directly to apta-
mers, several groups have evaluated aptamer probe accu-
mulation at tumor sites following systemic administration.
Shi et al. generated a Cy5-labeled TD05 aptamer, whichbinds specifically to the IgM heavy chain on Ramos cells.
Following tail-vein injection into Ramos tumor-bearing
mice, fluorescent signal in non-target tissues faded after
4 hours, while the signal at the tumor site remained
noticeable even after 6 hours [49]. The specific aptamer
binding promoted prolonged fluorescent signal, enab-
ling the determination of the tumor location. Savla et al.
verified that Muc1 aptamer conjugation, allowed QDs
to accumulate more specifically at the tumor site than
other organs 24 hours following their injection to an
A2780/AD ovarian xenograft model [54]. Additionally,
an activatable probe has been developed based on the
Sgc8 aptamer which targets CCRF-CEM cells. Upon
target binding, the probe changes conformation to dis-
sociate the quencher from the fluorophore, resulting in
signal restoration. During the in vivo study with CCRF-
CEM tumor-bearing mice (shown in Figure 3), fluores-
cence was clearly visible at the tumor site between 15 to
Figure 2 Overview of aptamer probes application for cell tracking. Aptamers can be attached to therapeutic cells ex-vivo, to track their
bio-distribution, tropism and functions (e.g. differentiation for stem cell) following their implantation. Additionally, aptamer conjugates can be
systemically introduced to specifically locate and longitudinally monitor diseased cells (e.g. metastatic cancer cells).
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which yielded higher background signals on non-tumor
tissues, the activatable probe was highly promising to
significantly enhance imaging contrast and reduce diag-
nosis time [55].
Simultaneous detection of various cancer cell types
is another useful application of aptamer biosensors.
This was achieved previously through optical means
in vitro, by labeling the different cancer cells with
distinct aptamer-conjugated fluorescent NPs. Kang et al.
conjugated three aptamers: AS1411 (targeting nucleolin),
TTA1 (for tenascin-C), and MUC-1 (for mucin) with three
QDs of distinct emission (605, 655, and 705 nm) to
identify five cancer cell types based on the differential
expression of their respective biomarkers [56]. Mean-
while, Chen et al. were able to simultaneously detect
Ramos, CEM and Toledo cancer cells from a cell mix-
ture, by applying three FRET NPs modified with distinct
aptamer (TD05, Sgc8, and T1, respectively) [57].
As for PET/SPECT monitoring, aptamer conjugation
has been used to enable control over the biodistribution
of radio-isotope tracers. Previously, aptamers generated
against activated neutrophil elastase NX21909 were labeled
with 99mTc, to monitor inflammatory events in a rat [58].
In a similar manner, an aptamer against tenascin-c (TTA1)
was labeled with Rhodamine red and 99mTc to track
glioblastoma (U251) and breast cancer (MDA-MB-436)
cells. Following intravenous injection, the aptamer sensors
showed rapid accumulation at tumor site within 10 -
minutes and diffused throughout 3 hours after. Therapid tumor uptake, in conjunction with rapid renal/
hepatic clearance, resulted in a high tumor to blood
signal ratio (~50 in 3 hours) [59]. Pieve et al. also
explored the potential usage of antiMUC1-aptamers as a
radiolabelling agent for breast cancer. Selected aptamers
which were conjugated with MAG2 ligand and labeled
with 99mTc, demonstrated great accumulation at the tumor
site of MCF-7 tumor-bearing mice [60]. More recently,
conjugation of the A10-3 RNA aptamer with 64Cu
through several chelators was shown in vitro not to
compromise A10-3 specificity towards PSMA positive
tumor, therefore being another promising candidate for
aptamer radiolabeling [61].
For cell tracking via X-ray/CT, findings that AuNP has
greater X-ray absorption compared to iodine-based con-
trast agents with less tissue interference and cytotoxic
effects have encouraged aptamer-AuNP probe utilization
[62,63]. Kim et al. developed a bifunctional aptamer
AuNP probe for combined prostate cancer imaging and
treatment. Particularly, the A9 aptamer was extended
to allow conjugation of a Dox loaded-21-nt (GCA)7
linker, with thiol modification for subsequent AuNP
attachment. The NPs increased CT intensity by 4 folds in
PSMA positive LNCaP cells when compared to control
PC3 cells, indicating a promising selective CT contrast
agent [64]. This report showcases the potential of
achieving an integrative aptamer probe to promote
drug localization as well.
Similarly, magnetic NP-aptamer conjugates are promis-
ing candidates in MRI. For example, Ko et al. conjugated
Figure 3 (See legend on next page.)
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Figure 3 Activatable aptamer probe (AAP) for in vivo cancer tracking. A) Schematic showing the mechanism of AAP recognition against
CCRF-CEM cells. Upon specific binding, the Sgc8 aptamer-containing AAP exhibited conformation alteration, which resulted in fluorescent restoration.
B) Flow cytometry data shows the specificity of AAP binding towards CCRF-CEM cells. As comparison, the signal from control probes with no affinity
was shown. C) Specific in vivo CCRF-CEM tumor imaging with AAP. One hour following their intravenous injection, AAP accumulated pre-dominantly
on CCRF-CEM tumor sites (labeled with pink circle), but not to control Ramos tumors. D) Longitudinal imaging of CCRF-CEM tumor with AAP revealed
clear tumor signal between 5 to 120 minutes post-intravenous injection. In comparison, control and “always-on” probe did not show specific
fluorescent signal at tumor site. Adapted with permission from ref. [55]. Shi H, He X, Wang K, Wu X, Ye X, Guo Q, Tan W, Qing Z, Yang X, Zhou B:
Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration.
Proceedings of the National Academy of Sciences 2011, 108:3900–3905. Copyright 2011 by National Academy of Sciences, USA.
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netic fluorescent cobalt-ferrite NPs. After intravenous
injection into tumor-bearing mice, the NPs showed
accumulation at tumor site, observable by both scintig-
raphy and T2-weighted MR. The incorporation of the
AS1411 aptamer led to a strong radionuclide signal with
increased T2 signal at the tumor region. In contrast,
mutant aptamer AS1411mt (with substituted G core
nucleotides) was ejected rapidly from the bloodstream
with no accumulation at tumor sites, demonstrating the
usefulness of specific binding moieties in tumor detec-
tion [33]. In other studies of MRI-based cancer cell
tracking, aptamers have been conjugated with superpar-
amanetic iron oxide nanoparticles (SPION) to modify the
magnetic relaxation time of the specific cancer cells. Wang
et al. showed that anti-PSMA A10 aptamer conjugated-
SPION significantly decreased both relaxation times
(T1 & T2) of target LNCaP cells, as compared to control
PC3 cells [42]. Jalalian et al. also showed great enhance-
ment of T1 weighted MR signal in C26 tumor area, when
5TR1 aptamer targeting Mucin 1 SPION complex was
used for simultaneous imaging and Epirubicin drug
delivery [65].
Aside from the examples mentioned above, there
exist more aptamers targeting upregulated receptors on
cancer cells, although their utilization for in vivo cell
tracking is still limited. These include the GS24, J18,
AIR-3A and Sgc8 aptamers, which are respectively
targeted to well-known receptors namely transferin
receptor (TfR), epidermal growth factor receptor (EGFR),
interleukin-6 receptor (IL-6R), and tyrosine kinase recep-
tor 7 (PTK 7) [66-69]. Given that these receptors are
closely related to the progression of various cancers (e.g.
ovarian, hepatocellular carcinoma, and acute lympho-
blastic leukemia (ALL) [70-72]), further application of
these aptamers as cancer tracking probes in vivo should
be very exciting. Not only do aptamer probes reveal the
tumor location and status, they can also help to hinder
tumor growth when utilized in conjunction with thera-
peutics for effective drug delivery [71,72].
Aptamers for tracking stem cells
Besides their applications for cancer cells, aptamers have
also been explored in the stem cell field, particularlybecause of the increasingly important role of stem cells
in regenerative medicine. To date, stem cells have been
incorporated in vivo for both tissue engineering and cell
therapy purposes. Seeded on scaffolds, these stem cells
can be expanded in vitro to achieve functional tissues
for later implantation [73-75]. Additionally, these stem
cells (without biomaterials) can be solely injected as cell
therapy. Mesenchymal stem cells (MSCs) in particular are
achieving acclaim for their immunomodulatory properties.
Aside from being multi-potent stem cells which can
differentiate to several cell types, MSCs can either pro-
mote or suppress the inflammatory response [76,77].
Consequently, they can escape allogeneic rejection, and
have been applied to promote wound-healing or in
conjunction with graft placement to suppress the graft-
versus-host disease (GVHD) [78,79]. In addition, some
have even reported their role in suppressing cancer cell
growth [80,81].
One usage of aptamers for stem cell applications is to
assist their isolation from the body. Noting that stem
cells exist in such a small fraction (e.g. MSC exists
approximately in a ratio of 1:100,000 to bone marrow
cells in teenagers) [73], a highly specific and sensitive
aptamer recognition platform is useful to generate a
homogenous pool of stem cells. Guo et al. managed to
isolate adult mesenchymal stem cells (aMSCs) from the
bone marrow cell mixture utilizing both aptamer-assisted
magnetic sorting and aptamer-assisted fluorescence
activated cell sorting (FACS). Due to the lack of specific
surface markers of aMSCs, they initially utilized cell-
SELEX to isolate aptamers with high binding affinity
compared to peripheral blood cells. One aptamer
sequence, G8 was chosen for further studies. For the
magnetic column fishing experiment, biotinalyted G8
was used to specifically label aMSCs with streptavidin-
coated magnetic Dynabeads®. Similarly, the G8 aptamer
was fluorescein isothiocyanate (FITC)-labeled to enable
FACS. This aptamer-enabled separation method resulted
in isolation of aMSCs with correct marker staining
showing CD29+, CD44+, CD45−, CD90+, SLA class I+,
SLA DQ−, and SLA DR− [82]. Subsequently, they applied
their apt-magnetic beads labeling for in vivo aMSCs
tracking. 20 hours post-injection, the labeled cells were
observed with MRI to disperse throughout the myocardium
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bution area. Moreover, histological examination of the
biopsies confirmed the presence of labeled aMSCs at
the identified area [83].
Aptamer labeling can alternatively be applied to moni-
tor the differentiation process of stem cells, as shown by
Iwagawa et al. [35]. Their selected aptamers (L1-65, L2-2
and L3-3) showed specific binding affinity to mouse
embryonic stem cells (mESCs), with low affinity towards
differentiated cell lines. During the course of retinoic acid
(RA) differentiation, multiple injections of the aptamer
showed declining cell affinity with progressive decrease
of fluorescent signal. Applying the same principle, stem
cells can potentially be incubated and tagged with simi-
lar aptamer probes prior to their injection to facilitate
colorimetric evaluation of successful cell differentiation.
Cellular interaction of stem cells with native host cells
(e.g. through factor secretion) is another important com-
ponent which determines the success of regenerative
medicine. PDGF for example, is particularly important
for MSC signaling, as it participates in MSC communi-
cation with activated endothelial cells and recruits them
to localize at inflamed tissue or tumors [84,85]. To this
end, Zhao et al. developed an aptamer biosensor to
recognize PDGF in the extracellular environment to
better understand MSC recruitment and signaling (shown
in Figure 4). Facilitated by amine-biotin-streptavidin inter-
actions, PDGF-sensitive aptamer beacons were conjugated
onto the surface of MSCs prior to their injection. This
aptamer was originally developed and optimized by Tan’s
group to specifically recognize PDGF, even in the pres-
ence of other proteins in the medium (e.g. bovine serum
albumin (BSA), lactate dehydrogenase (LDH)). As the
aptamer forms a complex structure upon PDGF bind-
ing, it can act as FRET/quench-based sensor that deter-
mine nearby PDGF concentration [86,87]. Through
monitoring the aptamer fluorescent signal, the interac-
tions experienced by the MSCs can be gauged, and the
cell localization site determined. In this study, the sensor-
engineered cells were detected in the BM of the mouse
24 hour post-transplantation [50]. In the future, similar
GF-responsive aptamers can even be used to direct the
homing of therapeutic cell to a particular diseased site.
Aptamers for tracking immune cells
Cell-based Immunotherapies are proven to be effective
for some diseases such as cancers. One type of immune
cells that has gained remarkable attention in the field is
the dendritic cells (DCs). DCs are specialized antigen-
presenting cells (APCs) with immunostimulatory recep-
tors which aid lymphocyte (T cell) activation. During
exposure to infections, immature DCs uptake pathogens,
degrade, and display their fragments to trigger further
immune responses (also known as DC maturation events)[88,89]. Exploiting these properties, DCs have been
utilized to elicit and control immunoregulatory cell
activity, especially in immune-related diseases [90,91].
To achieve successful cell therapy however, injected
DCs need to first migrate to the desired location and
survive, before executing their intended cellular function
[92,93]. Furthermore, the process of cell therapy such as
tuning of required cell number, injection frequency, and
administration strategies can be optimized by continuous
tracking [6,94,95]. Given their binding specificity and
versatility, potential incorporation of aptamers tracking in
DC-based therapy will be further discussed below.
To date, while there have been no significant reports
on aptamer biosensors application to track injected DCs
in vivo, there are several groups that have applied cell-
SELEX technique to identify aptamers with high specifi-
city to DCs. Berezovski et al. for example, carried the
selection process to isolate aptamers against immature
or mature dendritic cells (iDCs or mDCs), with 100 fold
greater affinity against the other DC type. Following which,
separation of mDCs from DC mixture was achieved
through FACS and streptavidin-coated magnetic beads
(shown in Figure 5), by tagging the aptamers with
biotin and Alexa-647 fluorophore [96]. Not only do the
mDCs aptamers assist in vitro DCs preparation (to ensure
maturation) prior to their injection, but the aptamer-
labeled mDCs can potentially be directed in vivo by
external magnets, as well as monitored through MRI.
SELEX can also be applied to identify aptamer se-
quences specific toward known DC ligands. As one
example, an aptamer targeting intercellular adhesion
molecule (ICAM-3) grabbing non-integrin (DC-SIGN)
ligand was selected with high affinity (Kd value 21.73
nmol/L) [97]. DC-SIGN has been identified previously
as an interesting ligand of DCs, as it allows pathogen
binding to escape the immune response [98]. Wengerter
et al. have also selected aptamers that recognize DEC205,
a C-type lectin which facilitates antigen cross-presentation
and CD8+ T cell activation [99]. By conjugating these
aptamers with a reporting probe and allowing them to
label DCs prior to their injection, the DCs localization
can be tracked and evaluated.
Aside from DCs, aptamer applications for immune cells
have also aimed at targeting T-cells. Several aptamers have
been previously identified for known receptors on acti-
vated T cells, including the 4-1BB, OX40, and CTLA-4
receptors [100-102]. Interestingly when introduced in vivo
as multivalent aptamer structures, the selected aptamers
in all three studies were capable of stimulating further
T-cell activities and inhibiting tumor growth. Applying
similar aptamers but labeled with imaging moieties,
subsequent labeling and tracking of the T-cell in vivo
can elucidate the processes by which the T-cell resides
and interferes with tumor growth.
Figure 4 Aptamer sensor probing stem cells’ niche environment and signalling. A) Schematic showing the detection of signaling molecules
using stem cell-conjugated aptamer probes. B) Aptamers were covalently attached to the cell through a streptavidin-biotin conjugation. C) Structure of
PDGF-sensitive aptamer probes used for this study. Upon specific binding with PDGF, the probe conformation is altered and the fluorescent signal of FAM
is quenched by Dabcyl. D) Representative fluorescent microscopy images of the sensor-tagged cells before and directly after the addition of 10 nM PDGF
in PBS. E) Real-time MDA-MB-231 cells’ PDGF secretion monitoring by apt-tagged MSCs. Left: experimental setup with microwells containing one sensor
MSC (red) with different numbers of PDGF-producing MDA-MB-231 cells (green). Here the secreted PDGF has been labeled with a GFP tag, while the apt
sensor is labeled with a red dye (Cy5). Right: declining MSCs’ fluorescence was observed during the course of PDGF production. The signal, which is
defined as the percentage of MSCs with <50% of their initial fluorescent intensity at any indicated time, correlates with the number of MDA-MB-231 cells.
Adapted with permission from ref. [50]. Zhao W, Schafer S, Choi J, Yamanaka YJ, Lombardi ML, Bose S, Carlson AL, Phillips JA, Teo W, Droujinine IA:
Cell-surface sensors for real-time probing of cellular environments. Nature nanotechnology 2011, 6:524–531. Copyright 2011 by Nature Publishing Group.
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Figure 5 Aptamer selection for immature (iDCs) and mature dendritic cells (mDCs). A) Flow cytometry characterization of aptamer pools’
binding to iDCs and EGFP-labeled mDCs after 10 rounds of selection. As evaluated through FC, aptamers selected for one DC type have 100-fold
affinity relative to the other DC type. B) Aptamer-facilitated mDCs isolation from iDCs with magnetic beads. (top) Flow cytometry assay of EGFP- iDCs
and EGFP +mDCs mixture with Alexa-647- and biotin-labeled mDC aptamers. (bottom) Flow cytometry assay following cell isolation with magnetic
beads. Cells left in supernatant are predominantly iDCs (left), while cells attached to the beads are mostly mDCs (right). Adapted with permission from
ref. [96]. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN: Aptamer-facilitated biomarker discovery (AptaBiD). Journal of the American
Chemical Society 2008, 130:9137–9143. Copyright 2008 by American Chemical Society.
Table 1 Challenges in aptamer biosensors
Challenges Possible solutions
Strategies to enhance in vivo
pharmacokinetics
- Formation of aptamer conjugates
- Aptamer chemical modifications
Loss of in vivo affinity for
in vitro selected aptamers
- Direct in vivo aptamer selection
- Adjusting in vitro selection conditions
to mimic closely in vivo conditions
(e.g. pH, temp)
- Polyvalent aptamer conjugates
Cost of aptamer biosensors - Minimizing aptamers length
- Utilize DNA-based aptamer
Safety of aptamer biosensors - Complete pre-clinical studies
- Negative selection with closely
related molecular targets
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While aptamers have attracted significant attention in
the field of cellular tracking, especially for cancer cells,
there are still several considerations that need to be
addressed prior to their clinical translation. These
include: 1) strategies to enhance in vivo pharmacokin-
etics, 2) loss of in vivo affinity for in vitro selected apta-
mers, 3) cost effectiveness of aptamer-based diagnosis,
and 4) safety aspect of aptamer biosensors. Below, we
will elaborate further on these challenges and propose
some solutions. The brief summary of these consider-
ations can be found in Table 1. Lastly, we have also
included our perspectives on the future of aptamer
technology for cell tracking.
Strategies to enhance in vivo pharmacokinetics
Since aptamers are small oligonucleotides with average
molecular weight between 10 to 15 kDa, they can be
subject to rapid nuclease degradation and blood clear-
ance, which significantly affect systemic delivery. Signals
from the aptamers (even when bound to their target) can
decay rapidly and are therefore not suited for prolonged
in vivo longitudinal monitoring [103-106]. Meanwhile for
some cell tracking applications, cells need to be monitoredover an extended period of time, such as stem cell track-
ing following implantation. To uncover the biodistribu-
tion of these cells, the labeling may need to last a few
hours. However to further monitor the growth and inte-
gration of the stem cells with host tissue, it might be
required to track the stem cells for at least a few weeks
[107,108]. In this case, conventional unmodified apta-
mers would be unsuitable.
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mers have previously been complexed with other entities
like NPs. The relatively large size of these conjugates,
coupled with the multivalent aptamers binding, facili-
tates faster accumulation at targeted cells and slower
elimination from the circulation [109,110]. Additionally,
chemical modifications can be made to prolong the
circulation half-life of aptamers. As an example, 40 kDa
poly-ethylene-glycol (PEG) molecules have been utilized
on the commercially available Macugen aptamer which
targets the vascular endothelial growth factors (VEGF)
[111]. Modifying the backbone of the aptamers to incorp-
orate protective groups such as 2’-fluoro, 2’-amino, or
2’-O-methyl can also help to improve nuclease resistance.
Given that nucleases cause significant aptamer degrad-
ation, these protective groups can be utilized to prolong
aptamer tracking/labeling window [112,113]. With these
chemical and physical modification tools already available,
one can expect significant improvement in the longitu-
dinal cell tracking properties of aptamers over the next
few years.
Loss of in vivo affinity for in vitro selected aptamers
As aptamer target binding involves conformational change
that is dependent on external conditions (e.g. pH, tem-
perature, etc.), the great discrepancy between in vivo patho-
physiological conditions and in vitro selection conditions
poses a significant issue. The high affinity of the in vitro
selected aptamers may be negated upon in vivo translations
[114-116]. One possible solution is to perform the aptamer
selection directly in vivo, although the complexity may
results in the need for more selection rounds [117,118].
However, in vitro-based selection might actually suffice,
provided the extracellular conditions are adjusted to closely
mimic the in vivo conditions [115,119].
Additionally, conjugating several aptamers together to
form multivalent aptamer structures have been shown to
assist in vivo targeting efficiency [99,100,120]. In the study
done by Wengerter et al., tetravalent DEC205-aptamer
streptavidin (SA) conjugates and not monovalent aptamer-
SA were observed to be uptaken by DEC205+ DCs in vivo.
Furthermore when linked with OVA for T-cell cross pres-
entation, only the tetravalent aptamer construct was
capable of eliciting T cell proliferation [99]. As an extension
to the multivalency effect of one aptamer type, conju-
gating multiple aptamers that recognize different recep-
tors/markers of the cells should also greatly enhance
aptamer binding affinity. As shown recently, multiple
aptamers cell labeling is very possible given that the
aptamers do not inhibit each other’s binding [121].
Cost effectiveness of aptamer diagnostics
Another factor to be considered for the translation of
aptamer biosensors is their cost. The unstable nature ofRNA oligonucleotides which results in short shelf-life
can significantly affect the manufacturing cost of apta-
mers [122]. Furthermore, large-scale generation of long
oligonucleotide sequences can be relatively difficult to
achieve via solid-phase-synthesis approaches. Chemical
modifications to their backbone also add to the cost of
aptamer biosensors [123,124]. Therefore, while recent
synthesis technology advancements have helped to de-
crease costs, cell-SELEX with shorter sequences should be
a viable alternative. Alternatively, sequence minimization
can be done following the selection process, to eliminate
non-critical regions [115,125,126]. In addition, noting that
DNA aptamers are relatively more stable compared to
RNA aptamers, DNA-based aptamers can be used with
less chemical modifications [104,127].
Safety of aptamer biosensors
While aptamers have been recognized to be low in
immunogenicity compared to most protein-based probes
or drugs, the safety aspect of aptamers remain to be care-
fully examined [128,129]. Aptamer binding to non-target
but similar molecules can trigger the activation of
undesired signaling pathways thereby interfering with
other aspects of cell status/function [104,130]. Thus for
future clinical translations, rigorous biocompatibility
studies need to be performed. Pre-clinical cytotoxicity
evaluation should be conducted on various cell types,
and a wide variety of pre-clinical animal subjects.
Especially when coupled with imaging moieties which
can be cytotoxic, preclinical studies should be used to
determine the threshold concentration of the aptamer
biosensors, at which no adverse side-effects will occur
[54]. Concurrently, negative selection with closely
related molecular targets should be included within the
cell-SELEX process to reduce the potential for non-
specific cross-binding [131].
Perspective: aptamers for cell tracking and assessment of
status/functions
With the rapid expansion of cell-SELEX technology
recently, it is conceivable that aptamer-based cell tracking
will expand significantly in the next couple of years. Aside
from the aspects of aptamers mentioned above that need
improvement, extending the applications of aptamers in
cell tracking can be vital. Applying the concept of aptamer
cell tracking in cell therapy to reveal interactions experi-
enced by the injected cells can shed significant light with
regards to the therapeutic process. It is commonly known
that cellular interactions play a major part in directing the
fate of injected cells [132-134]. In the example above,
surface-conjugated aptamers were utilized to study PDGF
signaling experienced by MSCs [50]. This can be extended
to study the effect of various signaling molecules for
both stem cells and immune cells therapy (e.g. tumor
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ally, aptamer has the potential to reveal direct cell-cell
communication. By conjugating two aptamers recognizing
different cell types for example, their interactions can be
studied through aptamer signal dynamics. Ultimately with
increased insight into post-transplantation interactions,
cell therapy can be greatly optimized. Alternatively,
aptamer tracking can be further applied to assist the
validation of therapeutic cells in vitro. Stem cell culture
typically undergoes a number of processing steps prior
to usage that may consist of (1) separation from a hetero-
geneous population or (2) undergo cell transformation
(i.e. differentiation) into a heterogeneous population.
In contrast, a cell population that bears a (or multiple)
homogenous therapeutically relevant biomarker is typ-
ically desired in therapy [137,138]. The selectivity of
aptamer-based cellular separation can be utilized to
enhance the purity of the implanted cell population.
Furthermore, quality assurance can also extend to the
identification of undesirable stem cells that generate
unwanted teratomas in vivo by using suitable aptamers.
Conclusions
Aptamer-based biosensors selected through cell-SELEX
can bring significant improvements to in vivo cellular
tracking. Aptamers with high binding affinities against
specific cancer antigens can be conjugated with various
imaging probes to trace the presence of a tumor mass
for cancer diagnosis, or with anti-cancer drugs for
targeted cancer treatment. In addition to revealing the
cancer types based on the detected molecular signa-
ture, aptamers provide a means to monitor cancer cells
in real time, towards a better understanding of various
cancer behaviors. Ultimately, this will lead to greater
efficiency in cancer treatment. Furthermore, for thera-
peutic cell applications, aptamer biosensors can facilitate
the monitoring of cellular processes following implantation,
while examining the bioactivities of therapeutic cells (e.g.
cell differentiation, protein secretion, etc.) can facilitate the
optimization process to achieve successful therapy.
Thus far, the reported usage of aptamer sensors for
stem and immune cell tracking is still minimal. While
many studies have been performed for diseased cancer
cell detection and therapy, little emphasis has so far
been placed on aptamers for injectable therapeutic cells.
Utilizing the cell-SELEX approach however, it is conceiv-
able that aptamer biosensors can be engineered to moni-
tor the process of therapeutic cells specified above (e.g.
maturation of DCs) of the therapeutic cells. As shown in
previous examples, aptamers highly specific to mature
DCs and MSCs have been selected and well applied for
their subsequent isolation.
Additionally while limitations in aptamer probe usage
remain, including the short circulation lifetime especiallyfor RNA-based aptamer and the difficulty to chemically
synthesize long oligonucleotides, these issues may not
significantly hinder their implementation. As discussed in
the previous section, various modification techniques have
been proposed to alleviate these limitations. Modifications
to the backbone of aptamers such as 2’-fluoro, 2’-ribo and
2’O-methyl RNA, have been shown to prolong their
circulatory lifetime, while conducting cell-SELEX from
a pool of short oligonucleotides facilitates simpler chem-
ical synthesis.
In the long run, successful development of aptamer
sensors can potentially be adapted into clinical applica-
tions and will assist the monitoring of diseased cells
from the host body or externally introduced therapeutic
cells. At the same time, the versatile nature of aptamer-
based probes can be harnessed as well for targeted treat-
ment in vivo, thereby realizing the notion of integrated
theranostic agents.
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